Category:
Description:
Indications:
-
Generalized
tonic-clonic seizures, simple or complex seizures, status epilepticus
-
Nonepileptic
seizures associated with Reye’s syndrome or after head trauma
-
Fosphenytoin-
substitute for oral phenytoin when PO administration not feasible;
migraines, Bell’s palsy, ventricular dysrhythmias,
-
Diabetic
neuropathy pain (non FDA approved)
Contraindications:
Precautions:
Adverse
Reactions (Side Effects):
-
CNS:
ataxia, confusion, dizziness, drowsiness, fatigue, headache, insomnia,
nystagmus, paresthesias, psychiatric changes, slurred speech
-
CV:
CV collapse (when drug administered too rapidly IV), hypotension,
ventricular fibrillation
-
EENT:
blurred vision, diplopia, gingival hyperplasia
-
GI:
anorexia, constipation, hepatitis, jaundice, nausea, vomiting, weight
loss
-
GU:
nephritis
-
MEME:
agranulocytosis, aplastic anemia, leukopenia, lymphadenopathy,
megaloblastic anemia, thrombocytopenia
-
METAB:
hyperglycemia
-
SKIN:
alopecia, hirsutism, lupus erythematosus, rash, Stevens-Johnson
syndrome
|
Dosage:
NOTE: Fosphenytoin 75mg
equivalent to 50mg phenytoin, after administration; the dose of IV
fosphenytoin is expressed as phenytoin equivalents (PE) to avoid the need
to perform molecular weight-based adjustments when converting between
fosphenytoin and phenytoin doses.
-
Adult:
Phenytoin
-
Seizures: IV loading dose 15-20 mg/kg based on recent dosing history and
serum levels, followed by 100mg PO or IV every 6-8 hours; PO
loading dose 1g divided 400mg, 300mg, 300mg given every 2 hours;
if load not necessary, may give 100mg 3 times daily, follow
levels; maintenance dose: 300mg daily or 5-6 mg/kg/day in divided
doses; once dosage established may use extended capsules and dose
daily
-
Neuritic
pain: PO 200-400mg daily
-
Fosphenytoin:
-
Status
epilepticus: IV 15-20mg PE/kg loading dose administered at
100-150mg PE/minute
-
Nonemergent
and maintenance dosing: IM/IV 10-20mg PE/kg loading dose
administered at a rate < or = 150mg PE/minute: maintenance
4-6mg PE/kg/day
-
Child:
Phenytoin
Special
considerations:
-
Therapeutic
range 10-20 mcg/ml; nystagmus appears at 20 mcg/ml, ataxia at 30
mcg/ml, dysarthria and lethargy at levels above 40 mcg/ml; lethal dose
2-5g
-
Pro-drug:
fosphenytoin rapidly converted to phenytoin in
vivo: minimal activity before conversion; water soluble, thus more
suitable for parenteral applications: doesn’t require cardiac
monitoring; can be administered at faster rate; no IV filter required;
compatible with both saline and dextrose mixtures; requires
refrigeration
|
The information contained here is an abbreviated summary. For more detailed
and complete information, consult the manufacturer's product information sheets
or standard textbooks.
Source:
Operational Medicine 2001, Health
Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau
of Medicine and Surgery, Department
of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300
OB-GYN 101:
Introductory Obstetrics & Gynecology
© 2003, 2004, 2005, 2008
Brookside Associates, LLC
All rights reserved
|